The Pharma Data

JANUARY 3, 2021

4, 2021 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Jan. Finnish time. About Nanoform. For more information please visit [link].

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. Finnish time.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

Further to XPhyto’s press release dated January 18, 2021, the Company’s core milestones for this year include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment in psychedelic medicine. About XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52